Wire · market
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 July 2026 · Fusion42 review
United Therapeutics announced its phase 3 study for ralinepag, a once-daily oral drug for pulmonary arterial hypertension (PAH), met its primary endpoint, reducing clinical worsening events by 55% versus placebo. The results, published in The Lancet, support the company's New Drug Application submitted to the FDA.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
The clinical benchmark for new pulmonary arterial hypertension drugs just got higher. If you are developing a competitor, you now need to prove your treatment works on top of a potent oral drug, not just older therapies.
◆ Coverage
1 source · 29 Jul 2026
◆ Related on Wire
◆ Topics